Danaher (DHR) analysis

Loading the Vaultflake…

Health is the debt acquisitions left, not a management system. Quality separates the consumable margin, which repeats, from the diagnostic, which is an order. Growth follows what the customer manufactures and what labs buy, and they need not rise together. P/E is read against a year of heavy production, not against that peak. Shareholder return, if any, comes after that debt. Do not read it as a consumable tied for life.

The P/E of a year of heavy biological production is not the earnings if the customer manufactures less. EV/EBITDA is read with the acquisition debt inside. Do not use Thermo Fisher's multiple as if diagnostics and a manufacturing contract were the same book. A dash if DHR is missing.

Limits of this report

Not advice on Danaher. Vaultflake does not describe the customer's process and does not treat the management method as the moat. Read the filings. The table is a snapshot, not a target price.

Questions from this report